AZ’s Dapagliflozin Closes On Canagliflozin With India’s SEC Nod
This article was originally published in PharmAsia News
Executive Summary
A new frontier in diabetes care is set to open in India with the Special Expert Committee giving a green light to AstraZeneca’s dapagliflozin, after holding back on safety concerns for a prolonged period.